BiomX Inc. (PHGE): Entry into a Material Definitive Agreement
BiomX Inc. (PHGE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001739174 0001739174 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
Amendment No. 1 extends maturity to Nov 1, 2026, accelerates part of principal via a $250k payment within two business days, and resolves accrued interest by issuing 800,000 restricted shares subject to listing clearance; Water IO waives retroactive default/acceleration risk.
Market read
This 8-K is a financing-term change that can affect near-term solvency perception and the company’s equity dilution path through a defined approval and longstop timeline.
What to watch
The share issuance is contingent on NYSE American clearance and corporate approvals, with a cash alternative after Aug 31, 2026, which can shift the timing and magnitude of dilution versus cash outflow.
Background
BiomX acquired ZorroNet on April 10, 2026 and issued a $1.25M promissory note to Water IO, originally maturing July 10, 2026.
Ticker impact
BiomX amended a $1.25M ZorroNet promissory note, extending maturity to Nov 1, 2026 and adding $250k principal payments plus 800k restricted shares.
Near-term downside risk may ease on the maturity extension, while dilution overhang could cap upside until the share issuance is confirmed.
The filing is a fresh 8-K disclosure with concrete payment schedule changes and a contingent equity issuance mechanism tied to regulatory/listing clearance and a cash fallback after Aug 31, 2026.
Market effects
Limited sector read-across; this is company-specific financing restructuring tied to an acquisition note.
No clear regional spillover beyond NYSE American-listed small-cap sentiment.
Minimal global relevance; impacts are confined to the issuer’s capital structure and counterparty settlement.
Counterpoint
The maturity extension may signal liquidity stress, and the contingent restricted-share issuance could be viewed as economically dilutive even if it avoids a near-term cash crunch.
Key entities
- issuerBiomX Inc.
NYSE American-listed company (PHGE) that entered Amendment No. 1 and Waiver to its promissory note.
- counterpartyWater IO Ltd.
Former owner of ZorroNet and holder of the promissory note; receives restricted shares and waives default/acceleration.
- acquisition targetZorroNet Ltd.
Acquired entity whose purchase consideration included the promissory note being amended.
